On 29 January 2021, the European Union regulators authorized the coronavirus vaccine for usage in all adults. This move came after the European Medicines Agency (EMA) was criticized for not moving promptly enough to vaccinate the people. But, concerns had also been expressed that not enough evidence exists to substantiate that the vaccine works well in geriatrics.

The EMA is suggesting two doses of the vaccine, with the second shot being administered 4-12 weeks following the initial dose. According to the European Union agency, the dosing regimen was demonstrated in trials to be efficacious and safe to prevent symptomatic coronavirus infection, with no serious cases and no hospitalizations more than 14 days following the second dosage.

This vaccine can be easily administered, is effective, has good tolerability, and completely safeguards against hospitalizations and serious disease. The European agency advocated the vaccine for usage in all adults. The European Union was expecting approval of the vaccine since it is cheaper and easier to handle when compared to some other vaccines. The European Union had already ordered 300 million dosages to be delivered following authorization and options for another 100 million dosages subsequently.